#efta01100297
LightNews LightNews
epsteinweb.bsky.social
Parts 1-4/4 — EFTA01100297.jpg
#epsteinweb #efta01100297
https://epsteinweb.org
Available in the iOS app store now!
https://apps.apple.com/us/app/epstein-web/id6758880661
EFTA01100261 | EFTA01100297 Editas Medicine I February 29, 2016 Morgan Stanley MORGAN STANLEY RESEARCH definitions below). To satisfy regulatory requirements, we correspond Own/might, ar most posithe stock rating, with a by recormendatim we correspond Equalweght and Not-Rated to hold and Lhdenveight to sell recce-emendations. respectitely. STOCK RATING CATEGORY COVERAGE UNIVERSE COUNT % OF TOTAL Overweight/Buy Equal-weight/Hold Not-Rated/Hold Underweight/Sell 1206 1432 79 658 TOTAL 3,375 36% 42% 2% 19% INVESTMENT BANKING GENTS (BC) COUNT 323 331 9 86 % OF TOTAL IBC 43% 44% 1% 11% % OF FtATING CATEGORY 27% 23% 11% 13% 749 Data include common stock and ALPS currently assigned ratings. thestrnal Balking giants we companies from when Morgan Staley received in estment balking compensation in the last 12 months. Analyst Stock Ratings Genteight (O). The stock's total retum is expected to exceed the average total rettm of the analyst's industry (a industry team's) cow-rage uriterse. on a risk-adjusted basis, ow the next 12-18 months. Equalweight (E). The stock's total return is expected to be in line with the average total return d the analyses industry (a industry team's) overage unhorse, on a risk-a:lusted basis, ow the next 12-18 maths. Not-Rated 0170. Currently the analyst does not lase adequate canictiat about the stock's total return relative to the avarage total ream of the analyst's industry (or industry team's) =wage unherse, on a risk-adjusted basis, ow the next 12-18 months. Undenveight (U). The stock's total return is expected to be below the menage total return of the analyses industry (a industry Wants) corsage urherse. on a risk-a:lusted basis, ow the next 12-18 maths. Unless otherwise specified, the time have for price targets included in Morgan Stanley Research is 12 to 18 molts. Analyst Industry Views Attracthe (AR The analyst expects the performance d his a her industry coverage uniwrse ow the next 12-18 months to be attractive te. the relevant broad market benchmark, as indcated below. Intine (I): The analyst expects the perfonmnce of his a her industry coverage wherse ow the next 12-18 months to be in line with the relaxant broad market benchmark, as indicated below. Carious (C): The analyst tows the performance of his a her industry coverage wherse ow the next 12-18 months with cautions. the relevant broad market benchmark, as indicated below. Benchmarks for each region we as follow: North America - S&P 500, Latin America - 'Stant MSG country index a MSCI Latin America Index: Europe MSCI Europe; Japan - tui,IX Asia - relevant MSCI country index a MSCI sub-regicnal index a MSCI AC Asia Pacific ex Japan Index. Important Disclosures for Morgan Stanley Smith Barney LLC Customers irpottant cisclosires regarding the relationship between the companies that am the subject of Morgan Staley Research and Morgan Stanley Srrith Barney LLC a Morgan Staley a any of their affiliates, are available en the Morgan Staley Wealth Management cksclosure website at www.maganstanley.conVonlinelresearchasclosures. Fa Morgan Stanley specific &desires, you may refer to www.morganstanley.comiresearchdiscloares. Each Morgan Stanley Eqtity Research report is reviewed and apposed on behalf of Morgan Stanley Smith Barney LLC. This review ad animal is caducted by the same person who relays the Equity Research report on behalf of Morgan Staley. This could create a conflict of interest. Other Important Disclosures Morgan Staley & Co. International PLC and its affiliates hate a significant financial interest in the debt securities d Amgen he., Biogen Inc, Celgene Cap, Glead Sciences Inc., Regenemn Pharmaceuticals Inc.. Morgan Staley is not acting as a municipal advisor and the opinions a dews contained herein are not intended to be, and do not constitute, advice within the meaning of Section 975 of the Dodd-Frank Wall Street Reform and Consumer Protection Act. Morgan Staley produces an expiry research product called a "Tactical Idea" Vohs contained in eTactical Idea' on a partictiar stock may be °eatery to the recommendations a dews expressed in research on the sane stock. This may be the rewinds:Hering time horizcns, methodologies. market everts, a ether factors. For all research available on a particular stock, please contact you- sales rep esentathe a go to Matrix at Ittp/Avww.maganstanley.conVmatrix. Morgan Staley Research is 'raided to air clients through ar acprietary research portal on Matrix and also elstnbtted electrcrically by Morgan Stanley to clients. Certain, but not all, Morgan Stanley Research prcducts we also made available to clients through third-party tend= or reckstributed to clients through alternate electronic means as a canenience. For access to all available Morgan Staley Research, please contact yam sales represented% ago to Matrix at Ntp://womvsnaganstanley.com/matrix. My access andror use of Morgan Staley Research is subject to Morgan Stanley's Terns of Use (htta/Aviwtmaganstantey.coraterms.htri). By accessing and/or using Morgan Staley Research. you are interim that you hate read ad agree to be bard by ar Terms of the (tittplAwviv.morganstanley.coMterms.html). In adation you consent to Morgan Staley processing your personal data and using cookies in accordance with our Privacy Policy and ow Global Cookies Policy (http://mwmagaistanley.comrprivacy_pledge.html). inducing fa the purposes of setting your preferences aid to collect readership data so that we can delis better and more personalized service and products to you. To find out nice intimater-I about hew Morgan Stanley processes personal data how we use cookies and how to reject cookies see our Privacy Policy and ar Globe Cookies Policy (tittplAwviv.morganstanley.caWahecy_pledge.html). If you do not agree to our Terms of Use ar /or if you do not wish to protide your cased to Morgan Staley processing yaw personal data or using cookies please do not access our research Morgan Staley Research does not amide ind‘idually tailored imestment advice. Morgan Stanley Research has been prepared without regard to the circumstances and objectives of thoselAtIO receive it. Mogan Staley recommends that investors independently ealuate particular investments and strategies, and encourages investors to seek the educe of a financial adviser. The appropriateness of an imestment a strategy will depend on an imesta's circumstances aid objectives. The securities, instruments, a strategies discussed in Morgan Staley Research may not be suitable for all Masters, and certain invastas may not be eligible to purchase a participate in sane or all of them. Morgan Staley Research is not an offer to buy a sell a the solicitation of an offer to buy or sell any security/instrument a to participate in any particular trading strategy. The are of and income from your investments may tray because of changes in interest rates. foreign exchange rates. default rates, prepayment rates, securities/instruments prices, market indexes, operational a financial conciticrs d calvaries or other factors. There may be time limitations on the exercise of options or other dais in securities/instruments transactions. Past performance is not necessarily a guide to future performance. Estimates of future paformance are based an assumptions that may not be realized. If provided, and unless otherwise stated, the closing price on the curer page is that of the primary exchange for the 37 EFTA01100297
May 9, 2026 at 11:08 AM